Dr Matthew Anderson, MD, PhD joined the Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford and Harrington Discovery Institute at University Hospitals dedicated to advancing rare disease breakthroughs, as Co-Director in early 2025. He holds the Sylvia K. Reitman Chair in Discovery and Innovation at Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, and is a Senior Attending Physician, and Professor of Pathology in the Division of Neuropathology at Case Western Reserve University. Dr Anderson is also a Visiting Professor at the University of Oxford.

Dr Anderson brings an extraordinary depth of expertise to the OHC mission, with a background that bridges medicine, neuroscience, and biotechnology. He holds a BS in Chemistry from Cornell College, followed by an MD and PhD from the University of Iowa, where he studied medicine, physiology, and biophysics. His training in pathology and neuropathology took him from the University of Iowa Hospitals to Harvard Medical School, where he later became Chief of Neuropathology.

He joined OHC from a position as VP and Head, Neuroscience Therapeutic Focus Area at Regeneron Pharmaceuticals, leading a team of 45 scientists. He has also conducted pioneering research in neuroscience and immunology as a research fellow at MIT with Nobel Laureate Susumu Tonegawa and in his own laboratory at Harvard Medical School.